References
- Hosokawa K, Takami A, Tsuji M, Araoka H, Ishiwata K, Takagi S, et al. Relative incidences and outcomes of Clostridium difficile infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. Transpl Infect Dis. 2014;16:412–20.
- Neeman K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminat Clostridium difficile infection in an allogenic stem cell transplant patient. Transpl Infect Dis. 2012;14:161–5.
- Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 2013;57:4501–5.
- El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012;44:228–30.
- Bosse’ D, Lemire C, Ruel J, Cantin AM, Me’nard F, Valiquette L. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection. Infection. 2013;41:579–82.
- Thomas A, Khan F, Uddin N, Wallace MR. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis. 2014;26:171–2.